Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-10
2005-05-10
Davis, Zinna Northington (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S432000, C514S451000, C546S233000, C549S013000, C549S426000
Reexamination Certificate
active
06890937
ABSTRACT:
A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. The administered enzyme inhibitor corresponds in structure to formula (I), below, or a pharmaceutically acceptable salt thereof, wherein R1and R2are both hydrido or R1and R2together with the atoms to which they are bonded form a 5- to 8-membered ring containing one, two, or three heteroatoms in the ring that are oxygen, sulfur, or nitrogen. R3in formula (I) is an optionally substituted aryl or optionally substituted heteroaryl radical. Also disclosed are metalloprotease inhibitor compounds having those selective activities, processes for manufacture of such compounds and pharmaceutical compositions using an inhibitor.
REFERENCES:
patent: 4595700 (1986-06-01), Donald et al.
patent: 5932595 (1999-08-01), Bender et al.
patent: 6013649 (2000-01-01), Freskos et al.
patent: 6268379 (2001-07-01), Xue et al.
patent: 6300514 (2001-10-01), Takahashi et al.
patent: 6541489 (2003-04-01), Barta et al.
patent: 20010014688 (2001-08-01), Barta et al.
patent: 20010039287 (2001-11-01), Barta et al.
patent: 20020177588 (2002-11-01), Barta et al.
patent: 20030073718 (2003-04-01), Barta et al.
patent: 0 266 182 (1988-05-01), None
patent: 0 606 046 (1994-07-01), None
patent: 0 780 386 (1997-06-01), None
patent: 0 930 067 (1999-07-01), None
patent: 4-338331 (1992-11-01), None
patent: WO 9005718 (1990-05-01), None
patent: WO 9320047 (1993-10-01), None
patent: WO 9402466 (1994-02-01), None
patent: WO 9424140 (1994-10-01), None
patent: WO 9509841 (1995-04-01), None
patent: WO 9513289 (1995-05-01), None
patent: WO 9529892 (1995-11-01), None
patent: WO 9606074 (1996-02-01), None
patent: WO 9611209 (1996-04-01), None
patent: WO 9720824 (1997-06-01), None
patent: WO 9724117 (1997-07-01), None
patent: WO 9837877 (1998-09-01), None
patent: WO 9838163 (1998-09-01), None
patent: WO 9909000 (1999-02-01), None
patent: WO 9942436 (1999-08-01), None
patent: WO 0046221 (2000-08-01), None
patent: WO 0059874 (2000-10-01), None
Brown, “Synthetic Inhibitors of Matrix Metalloproteinases”;Matrix Metalloproteinases, pp. 243-261 (Academic Press, Eds Park, W.C., & Mecham, R.P., 1998).
Dack et al., “Preparation of N-hydroxytetrahydropyridylsulfonylacetamides and related compounds as matrix metalloprotease inhibitors”, CA 131:44740 (1999).
Denis et al.,Matrix metalloproteinase inhibitors: Present achievements and future prospects, Invest. New Drugs, 15:175-185 (1997).
Gearing et al.,Processing of tumour necrosis factorα precursor by metalloproteinases, Nature, 370:555-557 (1994).
Kenyon et al.,A Model of Angiogenesis in the Mouse Cornea; Investigative Ophthalmology & Visual vol. 37, No. 8:1625-32 (Jul. 1996).
Knight et al.,A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases, FEBS Lett. 296(3):263-266 (1992).
Luckow et al.,Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in escherihia coli, J. Virol. 67(8):4566-4579 (1993).
McClure et al.,Matrix metalloprotease(MMP)-13 selective inhibitors for treatment of arthritis deformans and other MMP-related diseases, CA 131:125454 (1999) [CA Plus Accession No. 1999:468334].
McGeehan et al.,Regulation of tumor necrosis factorα processing by a metalloproteinase inhibitor: Nature, 370:558-561 (1994).
Mitchell et al.,Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage, J. Clin. Invest., 97(3):761-768 (1996).
Rasmussen et al.,Matrix metalloproteinase Inhibiton as a novel anticancer strategy: a review with special focus on batimastat and marimastat, Pharmacol. Ther., 75(1):69-75 (1997).
Reboul et al.,The new collagenase, collagnease-3, is expressed and synthesized by human chondrocytes but not by synoviocytes, J. Clin. Invest., 97(9):2011-2019 (1996).
Schwartz et al.,Synthetic inhibitors of bacterial and mammalian interstitial collagenases, Prog. in Med. Chem., 29:271-334 (1992).
Woessner, “The Matrix Metalloproteinase Family”,Matrix Metalloproteinases, pp. 1-14 (Academic Press, Eds. Parks, W.C. & Mecham, R.P., 1998).
Barta Thomas E.
Becker Daniel P.
Bedell Louis J.
Boehm Terri L.
Carroll Jeffery N.
Davis Zinna Northington
Harness & Dickey & Pierce P.L.C.
Pharmacia Corporation
LandOfFree
Aromatic sulfone hydroxamic acid metalloprotease inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aromatic sulfone hydroxamic acid metalloprotease inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aromatic sulfone hydroxamic acid metalloprotease inhibitor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3431184